BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s share price traded up 4.6% during mid-day trading on Friday . The company traded as high as $3.63 and last traded at $3.62, with a volume of 951,499 shares changing hands. The stock had previously closed at $3.46.

A number of equities analysts have issued reports on the company. Jefferies Group raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, June 1st. FBR & Co reaffirmed a “buy” rating and set a $6.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, July 6th. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, May 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.70.

The firm’s market capitalization is $266.77 million. The stock’s 50 day moving average price is $2.98 and its 200-day moving average price is $3.42.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.08. The firm had revenue of $4.82 million for the quarter, compared to the consensus estimate of $5.42 million. The company’s revenue was down 29.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.21) EPS. Equities research analysts expect that BioCryst Pharmaceuticals Inc. will post ($1.06) EPS for the current fiscal year.

Several hedge funds recently modified their holdings of the stock. Morgan Stanley raised its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares in the last quarter. Globeflex Capital L P bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $1,241,000. Finally, Jennison Associates LLC raised its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares in the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.